K Cusi, S Isaacs, D Barb, R Basu, S Caprio… - Endocrine Practice, 2022 - Elsevier
Objective To provide evidence-based recommendations regarding the diagnosis and management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …
E Braunwald - New England Journal of Medicine, 2022 - Mass Medical Soc
Gliflozins in Cardiac and Renal Disease Gliflozins—sodium–glucose cotransporter 2 inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …
Heart failure (HF) has been recognized as a common complication of diabetes, with a prevalence of up to 22% in individuals with diabetes and increasing incidence rates. Data …
MJ Davies, VR Aroda, BS Collins, RA Gabbay… - Diabetes …, 2022 - Am Diabetes Assoc
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of …
Abstract The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the …
H Han, Y Wang, T Li, C Feng, C Kaliszewski… - Diabetes …, 2023 - Am Diabetes Assoc
OBJECTIVE People with type 2 diabetes may have insufficient or prolonged sleep that could accelerate cardiovascular disease (CVD) onset, but existing evidence from prospective …
IH de Boer, K Khunti, T Sadusky, KR Tuttle… - Diabetes …, 2022 - Am Diabetes Assoc
People with diabetes and chronic kidney disease (CKD) are at high risk for kidney failure, atherosclerotic cardiovascular disease, heart failure, and premature mortality. Recent …
Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus. These high-risk patients benefit from aggressive risk factor …
Patients with type 2 diabetes mellitus (T2DM) can have multiple comorbidities and premature mortality due to atherosclerotic cardiovascular disease, hospitalization with heart …